Resideo Q1 2026 Results Beat, Signaling Execution Improvement

What happened

Resideo reported Q1 2026 net revenue of $1.91B, up 8% YoY and above the high-end of its outlook, with both Products & Solutions and ADI segments growing 9% and 8% respectively. Net income improved to $38M from $6M in Q1 2025, and adjusted EBITDA rose 28% to $215M, also above guidance. Gross margin held at 28.8%, with the P&S segment achieving its 12th consecutive quarter of YoY gross margin expansion. This performance marks a sharp turnaround from the $825M GAAP loss in Q2 2025, suggesting that integration synergies from the Snap One/Control4 acquisition and the company's distribution scale are beginning to deliver sustainable earnings growth. However, the large current indemnification obligation of $1.625B remains a balance sheet overhang that requires careful monitoring.

Implication

The strong Q1 beat reinforces that Resideo's strategic initiatives—including ADI cross-selling and Control4 integration—are driving real revenue and margin upside, justifying a shift from a neutral to a more positive stance. With adjusted EPS of $0.65 exceeding guidance and EBITDA margins expanding, the company is generating cash flow that can gradually reduce leverage (net debt/EBITDA at 3.01x) and address the indemnification obligations. Investors should watch for sustained momentum in P&S gross margin and continued growth in ADI's distribution business as proof of durable competitive advantages. The valuation, while not cheap at ~21x EV/EBITDA, becomes more justifiable if free cash flow trends upward from the $220M seen in Q2 2025. That said, the $1.625B indemnification liability still poses a risk; any adverse development could quickly reverse the sentiment.

Thesis delta

The Q1 2026 results materially improve the investment thesis by demonstrating that the company can deliver profit growth and margin expansion despite macro headwinds and the previously alarming GAAP loss. The evidence of integration synergies and strong operational performance reduces the risk of thesis invalidation and supports a more constructive view. However, we remain cautious on the indemnification overhang and want to see consistent cash flow to fully de-risk the balance sheet.